Regulatory milestones

Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a non-animal source.